Journal Watch · Journal of Controlled Release · 2026
Self-disintegrating electrospun short fibers as intra-articular drug depots for gouty arthritis.
Overall, self-disintegrating AcDEX short fibers offer a simple and tunable, shape-engineered intra-articular depot for local modulation of ROS and inflammation, with potential utility for gouty arthritis and other inflammatory joint disorders.
TL;DR
Overall, self-disintegrating AcDEX short fibers offer a simple and tunable, shape-engineered intra-articular depot for local modulation of ROS and inflammation, with potential utility for gouty arthritis and other inflammatory joint disorders.
Key findings
- In a gouty arthritis model, a single intra-articular injection of RES@AcDEX short fibers reduced swelling, improved gait performance, downregulated proinflammatory cytokines, and upregulated anti-inflammatory cytokines in periarticular tissues.
- Overall, self-disintegrating AcDEX short fibers offer a simple and tunable, shape-engineered intra-articular depot for local modulation of ROS and inflammation, with potential utility for gouty arthritis and other inflammatory joint disorders.
What they did
Resveratrol (RES), a hydrophobic antioxidant and anti-inflammatory compound, was encapsulated into AcDEX by blend electrospinning. RES@AcDEX fibers remained chemically intact during disintegration and provided sustained, pH-accelerated RES release (pH 6.8 vs 7.4) together with prolonged intra-articular retention, as evidenced by joint-confined fluorescence detectable for up to 10 days after injection. Released RES scavenged reactive oxygen species (ROS) in a dose-dependent manner, reduced intracellular ROS in lipopolysaccharide (LPS)-stimulated macrophages, and modulated inflammatory macrophage phenotypes in vitro.
Full abstract (original)
Background: Effective intra-articular therapy requires injectable depots that persist in the synovial space and modulate local inflammatory and oxidative microenvironments. Here, we developed a high-aspect-ratio short-fiber platform based on acid-labile acetalated dextran (AcDEX) for sustained intra-articular drug delivery. Continuous AcDEX fibermats electrospun from low-molecular-weight (10 kDa) dextran self-disintegrated within seconds into injectable short fibers (average aspect ratio ∼ 30) upon mild agitation in aqueous media, enabling on-demand preparation without post-processing.
What they did: Resveratrol (RES), a hydrophobic antioxidant and anti-inflammatory compound, was encapsulated into AcDEX by blend electrospinning. RES@AcDEX fibers remained chemically intact during disintegration and provided sustained, pH-accelerated RES release (pH 6.8 vs 7.4) together with prolonged intra-articular retention, as evidenced by joint-confined fluorescence detectable for up to 10 days after injection. Released RES scavenged reactive oxygen species (ROS) in a dose-dependent manner, reduced intracellular ROS in lipopolysaccharide (LPS)-stimulated macrophages, and modulated inflammatory macrophage phenotypes in vitro.
Results & conclusions: In a gouty arthritis model, a single intra-articular injection of RES@AcDEX short fibers reduced swelling, improved gait performance, downregulated proinflammatory cytokines, and upregulated anti-inflammatory cytokines in periarticular tissues. Overall, self-disintegrating AcDEX short fibers offer a simple and tunable, shape-engineered intra-articular depot for local modulation of ROS and inflammation, with potential utility for gouty arthritis and other inflammatory joint disorders.
Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114817 · PubMed 41833923.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Controlled Release for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Controlled Release study find?
Overall, self-disintegrating AcDEX short fibers offer a simple and tunable, shape-engineered intra-articular depot for local modulation of ROS and inflammation, with potential utility for gouty arthritis and other inflammatory joint disorders.
What type of study is this?
It is a in-vitro / cell study, published in Journal of Controlled Release in 2026. Resveratrol (RES), a hydrophobic antioxidant and anti-inflammatory compound, was encapsulated into AcDEX by blend electrospinning.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.jconrel.2026.114817. PubMed ID: 41833923. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/self-disintegrating-electrospun-short-fibers-as-intra-articular-drug-dep-114817/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides